Obesity Buyouts, Biotech Jumps & Crypto‑Infra Threads Set to Shake Up the Close

September 22, 2025

DENVER, Colo., Sep 22, 2025 (247marketnews.com)- Time’s ticking toward market close, and these tickers are flashing for strong moves both now and in after‑hours. Here’s what to pull up on your radar.

Pfizer (NYSE:PFE) agreed to acquire Metsera (NASDAQ:MTSR) for $47.50 per share in cash, plus up to $22.50 per share in contingent value payments (milestones), in a deal that values Metsera at about $4.9B up front, or up to $7.3B with milestones.

VENU (NYSE:VENU) remains in the mix with its earlier announcement of launching a blockchain‑powered digital platform in early 2026, including soft ticketing, tokenized memberships, fan rewards, etc. The ambition is to sell 20 million+ tickets/year and generate around $2B in ticketing volume when fully scaled (25 amphitheaters + 15 indoor complexes).

Watch for volume spikes as investors reposition based on the crypto/tokenization angle and it appears that a large shorter is in a trap, as VENU is trading above the key #13 level.

Uranium Royalty (NASDAQ:UROY) is another listing that’s been taking the shorts to the cleaners over the past month.

MBX Biosciences (NASDAQ:MBX) more than doubled intraday after announcing strong clinical trial results for its experimental thyroid/hypoparathyroidism treatment, canvuparatide. In one trial 63% of participants maintained normal calcium levels over 12 weeks without additional hormone support; extension studies saw 79% responding. They plan to initiate a Phase 3 trial in 2026.

Applied Digital (NASDAQ:APLD) continues to ride the AI infrastructure and data centers wave, while Bakkt (NYSE:BKKT) is riding the crypto wave.

About Venu Holding Corporation

Venu Holding Corporation (NYSE American: VENU) is redefining the live entertainment landscape through a national network of premium amphitheaters powered by its Luxe FireSuites model. With partnerships like AEG and Aramark, and an active development pipeline of over $5 billion (including $1 billion underway), Venu is building the next generation of destination venues, where investors, fans, and artists come together in a hospitality-first experience.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

For the full 24/7 Market News VENU report and in-depth insights, visit: Read 24/7 Market News VENU Report/

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by paid by Microcap Advisory for providing ongoing XHLD market outreach and other services. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/ or go to https://247marketnews.com/ten-holdings-event-solutions/ for additional 247marketnews.com XHLD disclosure. 247 has been paid by Microcap Advisory for providing ongoing XHLD market outreach and other services. This press release may include technical analysis for instructional purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (XHLD, PFE, UROY, MSTR, MBX, BKKT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.